OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is...
Staff
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship...
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to...
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland
FORT MILL, S.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device...
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused...
PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics
MINNEAPOLIS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV;...
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7%...
Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
Clinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering...
Belite Bio to Participate in the 2025 Maxim Growth Summit
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development...
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025...
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated...
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International ConferenceAddition of TUS to...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial...
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously...
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative...
Conavi Medical to Present at the Planet MicroCap Showcase: TORONTO in partnership with MicroCapClub on Wednesday, October 22, 2025
TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage...
Verano Elevates Expanding Vape Product Portfolio with Exclusive, First-to-Market Launch of Revolutionary HYPHEN System
HYPHEN features brand new best-in-class technology that allows consumers to flex between extracts, size formats and brands through interchangeable vape...
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...